Loxo Oncology

109 articles about Loxo Oncology

• 

  ASCO 2018: Some of the Top Stories So Far

  6/4/2018

  With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.

• FDA Accepts Larotrectinib New Drug Application and Grants Priority Review

  5/29/2018

  Bayer announced today that the U.S.Food and Drug Administration (FDA) has accepted the New Drug Application (NDA).

• 

  FDA Accepts NDAs and Grants Priority Review to Loxo Oncology, Astellas Pharma and Catalyst Pharma...

  5/29/2018

  Following the long holiday weekend, three pharma companies began the week with good news as the U.S. Food and Drug Administration awarded their therapies with Priority Review Status.
• 

  Loxo Oncology Stocks Jump After Positive Data Released at ASCO Preview

  5/17/2018

  Loxo Oncology shares climbed 19 percent after data for its cancer drug LOXO-292 was released.

• Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

  4/11/2018

  Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform

• Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

  4/10/2018

  Expands Illumina’s oncology offerings for NextSeq™ 550Dx with a companion diagnostic version of TruSight™ Tumor 170 for solid tumors

• 

  Illumina and Loxo Oncology Join Forces to Develop Pan-Cancer Companion Diagnostics

  4/10/2018

  Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling. It will seek approval for a version of Illumina’s TruSight Tumor 170 as a companion diagnostic for Loxo Oncology’s larotrectinib and LOXO-292.
• 

  Loxo Downplays Cancer Drug's Sales Projections

  4/3/2018

  Loxo Oncology completed the rolling submission of its New Drug Application (INDA) to the U.S. FDA for larotrectinib for adult and pediatric metastatic solid tumors with an NTRK gene fusion. What has caught many investors, analysts and industry observers off-guard is the way the company has downpl...

• Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

  3/26/2018

  Bayer announced that its collaboration partner Loxo Oncology, Inc., has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of adult and pediatric patients.

• Loxo Oncology Initiates Rolling Submission of NDA to FDA for Larotrectinib for the Treatment of TRK Fusion Cancers

  12/20/2017

  The company expects to complete the NDA submission in early 2018.

• Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers

  12/4/2017

  These data are being presented today at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research in Atlanta.

• Bayer Release: Updated Larotrectinib Pediatric Phase I Clinical Trial Data Demonstrates Response in TRK Fusion Cancers

  12/4/2017

  These data are being presented today at the AACR Special Conference on Pediatric Cancer Research in Atlanta.

• 

  3 Biotechs That Have Investors Grinning at Thanksgiving Dinner This Year

  11/21/2017

  Investors have had a decent year, but some have much to be grateful for this Thanksgiving.
• 

  Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

  11/14/2017

  Loxo Oncology struck a deal with Bayer to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55B.

• Loxo Oncology Announces Third Quarter 2017 Financial Results

  11/2/2017

  The company reported financial results for the third quarter ended September 30, 2017.

• Loxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference Call

  10/26/2017

  Loxo Oncology management will host a conference call to discuss these financial results, in addition to recent updates on development and corporate activities.

• Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

  10/18/2017

  The full dataset is being reserved for a future publication.

• Loxo Oncology Announces Details Of LOXO-292 Abstract To Be Presented As Late-Breaking Presentation At The IASLC 18th World Conference On Lung Cancer

  9/28/2017

• Loxo Oncology Announces Second Quarter 2017 Financial Results

  8/8/2017

• Loxo Oncology To Announce Second Quarter 2017 Financial Results

  8/1/2017